L
Lutonix
New drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation
About Lutonix
Lutonix specializes in the development and commercialization of drug-coated balloons (DCBs) for angioplasty procedures. The company operates in the medical device market, primarily serving healthcare providers and medical institutions that perform vascular interventions. Lutonix's core product, the Lutonix DCB, is the first and only DCB to receive FDA approval for use in long lesions up to 300mm and dysfunctional arteriovenous (AV) fistulae. This product is designed to improve patient outcomes by reducing the need for repeat interventions compared to standard angioplasty.
Lutonix generates revenue through the sale of its DCBs, which are available in various sizes and configurations to meet the needs of different vascular conditions. The company also participates in clinical trials and maintains a global registry to provide evidence of the efficacy and safety of its products. By focusing on innovation and regulatory compliance, Lutonix aims to maintain its leadership position in the DCB market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Maple Grove, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 59.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Catheters, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2011 | $225M | $225M | C. R. Bard | — |
| SERIES C✓Equity / VC | Dec 2010 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for Lutonix is 0 monthly website visits. Lutonix's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors3 additional known investors
- CBC. R. Bard
RiverVest Venture Partners
Vensana Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lutonix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lutonix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.